Emerging Her2-Targeting Adcs In Bladder Cancer
112
0:57
What Are The Latest Biomarkers For Urothelial...
152
0:52
Her2-Targeting Adcs For Urothelial Carcinoma
40
0:24
Evaluating Her2 As A Biomarker In Urothelial...
42
6:20
The Future Of Molecular Profiling In Bladder...
32
1:13
Scientists Propose A Breast Cancer Drug For Some...
833
1:41
Challenges In Treating Her2-Mutant Lung Cancer...
123
1:06
Emerging Targets In Bladder Cancer Ev Pembro,...
154
9:15
Upper Tract Urothelial Cancer
14.562
2:47
Urothelial Carcinoma
36.237
0:09
Maintenance Lapatinib After First-Line...
137
1:37
Genomic Ays For Chemotherapy Decisions In...
1.008
1:38
Disitamab Vedotin Plus Pembrolizumab In Auc Her2...
244
8:23
Upper Tract Urothelial Carcinomas Part Ii...
2.487
12:33
Drug Repurposing In Her2 Breast Cancer
326
1:29
The Future Of Early Her2-Positive Management
80
2:42
Rc48-C016 Disitamab Vedotin & Toripalimab Vs...
61
1:33
Recent Advances In The Use Of Targeted Therapies...
162
1:23
Correlations Between Her2 Alterations And Pd-L1...
204
2:41
T-Dxd Vs T-Dm1 In High-Risk Her2 Breast Cancer...
1:51
Mountaineer Results Trastuzumab And Tucatinib For...
270
0:56
Disitamab Vedotin With Pembrolizumab Versus...
277
2:58
Antibody-Drug Conjugates In Urothelial Carcinoma
170
1:32
Role Of Ngs And Targeted Therapies Available In...
614
6:45
The Significance Of Tucatinib Trastuzumab As A...
Decision Factors For Choosing Early Her2-Positive...
5:42
Sgntuc-019 Tucatinib Trastuzumab For Previously...
191
2:21
Dr. Tolaney On Activity With Abemaciclib In...
258
Results For Neratinib Plus Capecitabine In Her2...
533
1:31
Dr. Hamilton On The Promise Of Tucatinib In Her2...
287
2:15
Adjuvant Treatment For High Risk Hr Breast Cancer...
516
0:29
Dr. Tolaney On Neoadjuvant Her2-Directed Therapy
65
1:25
Dr. Hamilton On The Efficacy Of Trastuzumab...
363
Urothelial Carcinoma Trial Data Presented At Asco...
69
4:00
Phase 23 Trial Of Maintenance Lapatinib For...
101
1:40
Her2 In Prognosis Of Brain Metastasis In Breast...
1.849
2:11
Rc48-C017 Disitamab Vedotin And Toripalimab In...
97
5:48
Dr. Oshaughnessy On The Utility Of Tucatinib In...
150
1:52
Recent Treatment Approvals For Metastatic And...
76
1:17
Recent Improvements In Her2-Targeting Adcs For...
66
3:34
